Ultragenyx Pharmaceutical (RARE) Stock Research

Wednesday

Ultragenyx price target raised by $2 at Canaccord, here's why

RARE

Aug 5, 7:17 AM

Ultragenyx price target lowered by $2 at Wells Fargo, here's why

RARE

Aug 5, 6:53 AM

Tuesday

Closing Bell Movers: SpaceX slips after first quarterly report as public company

+16

Aug 4, 6:11 PM

Ultragenyx reaffirms FY26 revenue view $730M-$760M, consensus $748.3M

RARE

Aug 4, 4:11 PM

Ultragenyx reports Q2 EPS ($0.90), consensus ($1.24)

RARE

Aug 4, 4:10 PM

Ultragenyx price target lowered by $8 at Guggenheim, here's why

RARE

Aug 4, 6:47 AM

Over a week ago

Ultragenyx price target raised by $4 at Wedbush, here's why

RARE

Jul 13, 8:05 AM

Ultragenyx price target raised by $5 at RBC Capital, here's why

RARE

Jul 7, 7:28 AM

Acting FDA head vows to block political interference, Endpoint News says

+23

Jun 4, 2:11 PM

FDA issues draft guidance to help accelerated cell, gene therapies for patients

+24

Jun 2, 9:40 AM

Ultragenyx price target raised by $12 at Cantor Fitzgerald, here's why

RARE

May 21, 7:14 AM

What You Missed On Wall Street On Tuesday

+47

May 12, 4:11 PM

Trump Trade: Trump to suspend tariff-rate quotas on beef imports

+33

May 12, 10:47 AM

Trump approves plan to fire FDA head Marty Makary, CBS reports

+13

May 11, 12:22 PM

Ultragenyx price target lowered by $1 at Evercore ISI

RARE

May 11, 8:10 AM

What You Missed On Wall Street On Friday

+37

May 8, 4:21 PM

Ultragenyx price target lowered by $1 at Wedbush, here's why

RARE

May 8, 9:36 AM

Ultragenyx price target lowered by $9 at Guggenheim, here's why

RARE

May 8, 7:14 AM

Ultragenyx reaffirms FY26 revenue view of $730M-$760M, consensus $746.25M

RARE

May 5, 4:27 PM

Ultragenyx reports Q1 EPS ($1.84), consensus ($1.46)

RARE

May 5, 4:26 PM

Ultragenyx price target lowered by $1 at Barclays, here's why

RARE

Apr 29, 5:43 AM

Ultragenyx price target raised by $17 at Morgan Stanley, here's why

RARE

Apr 16, 8:31 AM

Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says

+13

Apr 13, 3:33 PM

Ultragenyx UX111 AAV9 biologics license application accepted for FDA review

RARE

Apr 2, 9:04 AM

Ultragenyx announces FDA clearance of UX016 investigational new drug application

RARE

Mar 30, 9:18 AM

Specialized Rare Disease Focus: Ultragenyx exclusively targets rare and ultra-rare genetic diseases, cultivating deep expertise and focusing resources where unmet medical needs are significant and competition is often limited.

Diverse Therapeutic Modalities: The company develops therapies across various modalities, including small molecules, biologics, and gene therapies, demonstrating broad scientific capabilities and diversifying its development portfolio.

Established Commercial Infrastructure: With multiple approved products like Crysvita and Dojolvi, Ultragenyx possesses a specialized global commercial infrastructure experienced in launching and managing rare disease therapies.

Clinical Trial Failure and Delays: The company's drug candidates may fail to demonstrate efficacy or safety in ongoing or future clinical trials, or face unexpected delays in trial completion, potentially leading to significant financial losses and an inability to bring new therapies to market.

Regulatory Approval Challenges: Ultragenyx may fail to obtain or maintain necessary regulatory approvals from agencies like the FDA or EMA for its drug candidates, or face unexpected conditions on approval, hindering commercialization efforts.

Intense Market Competition: Despite focusing on rare diseases, Ultragenyx faces competition from other pharmaceutical companies developing similar therapies, potentially impacting market share, pricing power, and profitability of its approved or future products.

Charts